Obesity (BMI>30)NCT07684664
Allurion Gastric Balloon PAS
A study testing Active Elipse Device in people with Obesity (BMI>30) and Obesity & Overweight, run by Allurion Technologies.
Trial summary
The primary purpose of this study is to confirm the safety profile results for the Allurion Gastric Balloon System (AGBS). Read more about this study
- Who is it for?
- Ages 22 to 65 years
- Conditions the study is for
- Obesity (BMI>30), Obesity & Overweight
- What is being tested?
- Active Elipse Device
- Type of treatment
- Medical device
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 250 participants
- Where
- No sites listed yet
- Study dates
- 15 Jul 2026to 20 Apr 2029
- Phase
- Interventional
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 22 to 65 years
- All sexes
- No healthy volunteers
- Adult, Older adult
Who may be able to join
- Age ≥22 years and ≤ 65 years of age
- BMI ≥30 kg/m2 and ≤ 40 kg/m2
- Have signed study specific Informed Consent Form
- Willing to comply with study requirements, including follow-up visits
- Documented negative pregnancy test in women of childbearing potential
- Women of childbearing potential not intending to become pregnant for the duration of study participation. (Note: Women of childbearing potential must not be nursing at the time of treatment).
- Fully ambulatory without any severe chronic orthopedic disease that requires reliance on crutches, walkers or a wheelchair that could preclude exercise during the study
- At least one unsuccessful attempt at weight loss, such as self-administered, commercial, or medically supervised weight loss program attempted within the 24 months preceding enrollment
Who cannot join
- Contra-indications to intragastric balloon placement as outlined in Instructions for Use
- Any conditions that, in the opinion of the Investigator, may render the patient unable to complete the study, or lead to compliance with study requirements, or that might confound study data.
About this study
Official title: A Single-Arm, Multi-Center, US-based Study to Obtain Data Regarding the Safety and Effectiveness of the Allurion Gastric Balloon System in the Post-Market Setting
The primary purpose of this study is to confirm the safety profile results for the Allurion Gastric Balloon System (AGBS).
Read the detailed description
The primary endpoint of the study is to confirm the safety profile results for the Allurion Gastric Balloon System (AGBS) as obtained in the US pivotal clinical study, TRL-1000-0007. The safety endpoint is the percentage of patients who experience a Serious Adverse Event (SAE) that is device or procedure related.
The secondary endpoint is to evaluate device effectiveness after the sequential balloon therapy.
The effectiveness endpoints are evaluated as:
- the percentage of patients with at least 5% Total Body Weight Loss (%TBWL) (responder rate) and
- the mean %TBWL at 48 weeks.
- Conditions
- Obesity (BMI>30), Obesity & Overweight
- Being tested
- Active Elipse Device
- Medical subject headings
- Obesity, Overweight
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Active Elipse DeviceDevice
Intervention Device
| Study group | Role | What they receive |
|---|---|---|
| Treatment Arm | Experimental | All patients eligible to participate will receive the Elipse study device Receives: Device: Active Elipse Device |
What is being measured
The primary outcome is the main question the study is designed to answer.
Incidence of Procedure- or Device-Related Serious Adverse Events (SAEs)
Percentage of patients experiencing a procedure- or device-related Serious Adverse Event (Clavien-Dindo Class III or greater) through 48 weeks. The primary objective is to confirm the safety profile of the Allurion Gastric Balloon System (AGBS) in the commercial/post-market setting, consistent with results from the US pivotal study (AUDACITY). All adverse events are coded using MedDRA and classified using the Clavien-Dindo classification system. The endpoint is met if the upper bound of the exact two-sided 95% confidence interval falls below 10%. Analysis is performed on the ITT population (all patients for whom the deployment procedure is attempted).
Measured: Through 48 weeks (from first balloon placement on Day 0 through end of second balloon therapy period)
Secondary outcomes (2)
Responder Rate: Percentage of Patients With ≥5% Total Body Weight Loss (%TBWL)
Percentage of patients achieving at least 5% Total Body Weight Loss (%TBWL) at Week 48 (responder rate). %TBWL is calculated as 100 × (Weight on Day 0 - Weight at visit) / Weight on Day 0. This endpoint evaluates device effectiveness following sequential balloon therapy (up to two balloons). Analysis is performed on the modified Intent-to-Treat (mITT) population, defined as all patients who successfully received the Allurion Balloon and for whom the balloon was not known to be removed or exited the body within the first 12 weeks after placement. Responder rate is summarized as a proportion with a 95% two-sided exact confidence interval.
Measured: Week 48
Mean Percent Total Body Weight Loss (%TBWL)
Mean Percent Total Body Weight Loss (%TBWL) at Week 48 following sequential balloon therapy (up to two Allurion Balloons placed over the study period). %TBWL is calculated as 100 × (Weight on Day 0 - Weight at visit) / Weight on Day 0. This endpoint evaluates device effectiveness. Analysis is performed on the modified Intent-to-Treat (mITT) population and assessed with a 95% two-sided confidence interval using a mixed model of repeated measures (MMRM) approach.
Measured: Week 48
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted6 Jul 2026
- Study start15 Jul 2026 (estimated)
- Primary completion19 Feb 2029 (estimated)
- Study completion20 Apr 2029 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Obesity (BMI>30)Studies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Treatment
- Allocation
- Not applicable
- Intervention model
- Single group
- Masking
- None (open label)
- Enrolment
- 250 participants (estimated)
Sponsor and investigators
- Lead sponsor
- Allurion Technologies
- Sponsor type
- Industry (pharma, biotech, devices)
- Responsible party
- Sponsor
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07684664
- Sponsor's protocol ID
- TRL-1000-008
- Other IDs
- PAS001, P250023
- Status last verified
- Jun 2026
- First submitted
- 29 Jun 2026
- Last updated
- 6 Jul 2026
- Results posted
- No
- Data monitoring committee
- Yes
- FDA-regulated drug
- No
- FDA-regulated device
- Yes
- Individual data sharing
- Undecided
Study at a glance
From the registry record, last updated by the sponsor on 6 Jul 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- A Single-Arm, Multi-Center, US-based Study to Obtain Data Regarding the Safety and Effectiveness of the Allurion Gastric Balloon System in the Post-Market Setting
- ClinicalTrials.gov ID
- NCT07684664
- Acronym / sponsor ID
- TRL-1000-008
- Conditions
- Obesity (BMI>30), Obesity & Overweight
- Study type
- Interventional
- Recruitment status
- Not yet recruiting
- Enrolment
- 250 participants (estimated)
- Lead sponsor
- Allurion TechnologiesIndustry (pharma, biotech, devices)
- Study start
- 15 Jul 2026 (estimated)
- Primary completion
- 19 Feb 2029 (estimated)
- Study completion
- 20 Apr 2029 (estimated)
- First posted
- 6 Jul 2026 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
The primary purpose of this study is to confirm the safety profile results for the Allurion Gastric Balloon System (AGBS).
Detailed description
The primary endpoint of the study is to confirm the safety profile results for the Allurion Gastric Balloon System (AGBS) as obtained in the US pivotal clinical study, TRL-1000-0007. The safety endpoint is the percentage of patients who experience a Serious Adverse Event (SAE) that is device or procedure related.
The secondary endpoint is to evaluate device effectiveness after the sequential balloon therapy.
The effectiveness endpoints are evaluated as:
- the percentage of patients with at least 5% Total Body Weight Loss (%TBWL) (responder rate) and
- the mean %TBWL at 48 weeks.
Study design
- Primary purpose
- Treatment
- Allocation
- Not applicable
- Intervention model
- Single group
- Masking
- None (open label)
- Number of arms
- 1
| Arm | Type | Receives |
|---|---|---|
| Treatment Arm | Experimental | Device: Active Elipse DeviceAll patients eligible to participate will receive the Elipse study device |
Who may qualify
- Ages
- 22 to 65 years
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (8 listed)
- Age ≥22 years and ≤ 65 years of age
- BMI ≥30 kg/m2 and ≤ 40 kg/m2
- Have signed study specific Informed Consent Form
- Willing to comply with study requirements, including follow-up visits
- Documented negative pregnancy test in women of childbearing potential
Key exclusion criteria (2 listed)
- Contra-indications to intragastric balloon placement as outlined in Instructions for Use
- Any conditions that, in the opinion of the Investigator, may render the patient unable to complete the study, or lead to compliance with study requirements, or that might confound study data.
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Active Elipse DeviceIntervention Device | Device | Treatment Arm |
Primary outcome
Incidence of Procedure- or Device-Related Serious Adverse Events (SAEs)
Time frame: Through 48 weeks (from first balloon placement on Day 0 through end of second balloon therapy period)
Percentage of patients experiencing a procedure- or device-related Serious Adverse Event (Clavien-Dindo Class III or greater) through 48 weeks. The primary objective is to confirm the safety profile of the Allurion Gastric Balloon System (AGBS) in the commercial/post-market setting, consistent with results from the US pivotal study (AUDACITY). All adverse events are coded using MedDRA and classified using the Clavien-Dindo classification system. The endpoint is met if the upper bound of the exact two-sided 95% confidence interval falls below 10%. Analysis is performed on the ITT population (all patients for whom the deployment procedure is attempted).
2 secondary outcomes
Responder Rate: Percentage of Patients With ≥5% Total Body Weight Loss (%TBWL)
Time frame: Week 48
Mean Percent Total Body Weight Loss (%TBWL)
Time frame: Week 48
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 6 Jul 2026.
- Individual participant dataSharing planned: Undecided
Related trials for Obesity (BMI>30)
Active, not recruiting
Influence of the Urolithin A on the Population With BMI Higher Than 30 During Restricted Eating.
Obesity & Overweight
Active, not recruiting
Effects of a High-protein Diet and Resistance Training on Fat-mass Loss Maintenance
Obesity (Body Mass Index >30 kg/m2)
Not yet recruiting
Impact of Endoscopic Sleeve Gastroplasty (ESG) in Obese Adults With Type 2 Diabetes (T2D)
Type 2 Diabetes Mellitus (T2D), Obesity (BMI>30)
Recruiting
Investigation of Egg Intake and the Relationship Between Gut Microbiome, Metabolic, and Immune Profiles
Obesity (BMI Equal to or >30), Immune Function
RecruitingObservational study
Frontal EEG Dynamics During Anesthesia in Patients With Obesity and Normal Weight
Obesity (BMI>30), General Anesthesia
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
The record lists no contact. Use the official record to reach the sponsor.
Questions about this trial
What is this clinical trial studying?
A study testing Active Elipse Device in people with Obesity (BMI>30) and Obesity & Overweight, run by Allurion Technologies.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 8 inclusion and 2 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: opening soon, as of the sponsor's last update on 6 Jul 2026. Status can change between updates, so confirm with the study contact before making plans.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Incidence of Procedure- or Device-Related Serious Adverse Events (SAEs) (time frame: Through 48 weeks (from first balloon placement on Day 0 through end of second balloon therapy period)). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 6 Jul 2026.